Targeting insulin-like growth factor type 1 receptor in cancer therapy Journal Article
| Authors: | Atzori, F.; Traina, T. A.; Ionta, M. T.; Massidda, B. |
| Article Title: | Targeting insulin-like growth factor type 1 receptor in cancer therapy |
| Abstract: | It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting the IGF axis. We also reviewed the effects of two drugs that target the IGF-1R: monoclonal antibodies and tyrosine kinase inhibitors. Preliminary results of studies involving these agents provided a foundation for ongoing clinical trials, whose results in the near future will help us understand how to incorporate anti IGF-1R strategies into the current anticancer armamentarium. © 2009 Springer-Verlag. |
| Keywords: | osteosarcoma; signal transduction; unclassified drug; prednisone; clinical trial; constipation; fatigue; neutropenia; paresthesia; review; cisplatin; erlotinib; cancer combination chemotherapy; cancer risk; diarrhea; gastrointestinal hemorrhage; nonhuman; side effect; antineoplastic agents; gemcitabine; paclitaxel; pancreas cancer; antineoplastic agent; anorexia; neoplasms; colorectal cancer; carboplatin; unindexed drug; bortezomib; drug eruption; infection; multiple cycle treatment; multiple myeloma; ovary cancer; pain; breast cancer; anemia; protein targeting; lung non small cell cancer; nausea; thrombocytopenia; vomiting; weight reduction; lung cancer; dexamethasone; deep vein thrombosis; antineoplastic activity; chronic myeloid leukemia; cetuximab; cancer therapy; psoriasis; acute lymphoblastic leukemia; cancer resistance; clinical trials-phase i; clinical trials-phase ii; insulin-like growth factor 1 receptor; monoclonal antibodies; tyrosine kinase inhibitors; 3 bromo 5 tert butyl 4 hydroxybenzylidenemalononitrile; amg 479; ant 429; atl 1101; ave 1642; bms 536924; bms 554417; bvp 51004; cixutumumab; cp 751871; deforolimus; docetaxel; exemestane; imc a 12; insm 18; irinotecan; mk 0646; monoclonal antibody; osi 906; panitumumab; pf 299804; protein tyrosine kinase inhibitor; r 1507; robatumumab; sch 717454; somatomedin c receptor; temsirolimus; xl 228; abdominal pain; adrenal cortex carcinoma; alanine aminotransferase blood level; aminotransferase blood level; appetite; arthralgia; aspartate aminotransferase blood level; asthenia; backache; cancer hormone therapy; chill; colorectal carcinoma; coughing; digestive system cancer; dizziness; drug dose escalation; drug fever; drug hypersensitivity; drug receptor binding; dyspnea; ewing sarcoma; febrile neutropenia; feces color; fever; flushing; gamma glutamyl transferase blood level; hyperglycemia; hyperuricemia; hypomagnesemia; injection site reaction; liver carcinoma; loading drug dose; lymphocytopenia; nail disease; neuroendocrine tumor; pancreas carcinoma; pneumonia; prostate cancer; pruritus; purpura; rash; salmonellosis; sarcoma; syncope; tumor lysis syndrome; tumor pain; drug delivery systems; drug synergism; protein kinase inhibitors; receptor, igf type 1 |
| Journal Title: | Targeted Oncology |
| Volume: | 4 |
| Issue: | 4 |
| ISSN: | 1776-2596 |
| Publisher: | Springer |
| Date Published: | 2009-12-01 |
| Start Page: | 255 |
| End Page: | 266 |
| Language: | English |
| DOI: | 10.1007/s11523-009-0123-z |
| PUBMED: | 19876700 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 30 November 2010" - "Source: Scopus" |
